According to White et al. [61], triple therapy with HB-EGF-PlGF-2123–144, PDGF-BB-PlGF-2123–144, and VEGF-PlGF-2123–144 was effective against chronic non-healing diabetic wounds in a mouse model of type 1 diabetes [61]; see Table 16. This evidence concerns the gene GSTM1 and type 1 diabetes mellitus.